Speaker's Highlight

• Don Sin University of British Columbia, St. Paul Hospital (Canada)
  Kenneth R. Chapman Toronto General Hospital Research Institute (Canada)
• Parameswaran Nair McMaster University (Canada)
  Carolyn Calfee UCSF (U.S.A.)
• Gregory P. Downey University of Colorado School of Medicine (U.S.A.)
  David A. Schwartz University of Colorado School of Medicine (U.S.A.)
• Neil Schluger Tuberculosis Control Branch, California Department of Public Health (U.S.A.)
  Nick Kim Critical Care & Sleep Medicine, University of California San Diego (U.S.A.)
• Nicola Hananiah Baylor College of Medicine (U.S.A.)
  Jae-Joon Yim Seoul National University College of Medicine (Republic of Korea)
• Koichiro Asano Tokai University School of Medicine (Japan)
  Diahn-Warng Perng Taipei Veterans General Hospital (Taiwan)
• Konstantinos Kostikas University of Ioannina (Greece)
  Karin Klooster University Medical Center Groningen (Kingdom of the Netherlands)

• Bronchoalveolar lavage fluid analysis and interstitial lung disease

  Bronchoalveolar lavage has long provided clinicians with a window into the distal lung, but recent refinements in fluid analysis are sharpening its diagnostic value for interstitial lung diseases. Where the procedure was often relegated to a secondary test after high-resolution CT, contemporary workflows increasingly place cellular counts, lymphocyte subsets, protein signatures and microbial sequencing at the centre of the diagnostic pathway. The result is a more nuanced picture of alveolar inflammation that helps differentiate idiopathic pulmonary fibrosis from granulomatous, hypersensitivity and connective tissue disease-related processes.

  In Australia, where respiratory physicians balance large metropolitan catchments with vast rural and remote regions, these refinements carry particular weight. Centres such as Royal Prince Alfred in Sydney, The Alfred in Melbourne and the Royal Adelaide Hospital have built multidisciplinary discussion forums that integrate lavage findings, radiology and histopathology for complex referrals. At the same time, occupational exposures linked to engineered stone, mining and legacy asbestos, alongside recurring bushfire smoke events, continue to shape local case mixes. Refined fluid-based biomarkers now sit alongside imaging and serology, helping clinicians reach a confident working diagnosis even when surgical lung biopsy is felt to carry unacceptable risk.

  Cellular profiling and the modern differential

  The first signal clinicians still extract from lavage fluid is the cellular profile, yet thresholds and interpretations have matured. Total cell counts, the relative proportion of lymphocytes, neutrophils and the CD4/CD8 subset ratio remain the backbone of analysis. A lymphocyte-rich sample, particularly above fifteen percent, raises the possibility of sarcoidosis, drug-induced pneumonitis or hypersensitivity pneumonitis. A raised neutrophil fraction, by contrast, points toward acute exacerbation of fibrosis or aspiration-related injury, especially in older patients.

  Standardised reporting templates now encourage laboratories to accompany percentages with absolute counts and reference ranges calibrated to local equipment. This shift reduces the inter-laboratory variability that historically complicated comparisons between Australian teaching hospitals and regional processors. Harmonisation also helps when patients transition between centres during work-up, a scenario familiar to tertiary services in Brisbane and Perth where referrals arrive from hundreds of kilometres away.

  Molecular and proteomic layers

  Beyond the cellular landscape, protein and molecular markers extracted from lavage supernatant are reshaping diagnostic reasoning. Surfactant protein levels, Krebs von den Lungen-6 (KL-6) and CCL18 have moved from research curiosity toward clinically meaningful adjuncts, particularly in fibrotic phenotypes where imaging alone struggles to distinguish active inflammation from established scarring. Elevated KL-6 in lavage, paired with serum values, helps signal disease progression in idiopathic pulmonary fibrosis and connective tissue disease-related cases. These quantitative proteomic trajectories help serial monitoring, allowing clinicians in outpatient clinics across Adelaide or the Gold Coast to adjust treatment thresholds without resorting to repeated imaging or invasive sampling.

  Proteomic platforms are also being coupled with machine-learning classifiers that integrate dozens of variables into a single risk score. Early studies suggest these scores can flag progressive fibrosing behaviour months before a decline is visible on serial spirometry. For Australian multidisciplinary teams weighing transplant referral or antifibrotic therapy initiation, such early warning layers meaningfully shorten the decision pathway and reduce reliance on subjective pattern recognition.

  Microbiological and genomic sequencing

  The microbiome component of lavage analysis has been transformed by next-generation sequencing. Broad-range 16S PCR, complemented by shotgun metagenomics in immunocompromised hosts, can identify bacterial, mycobacterial and fungal signatures that previously escaped routine culture. In patients with suspected hypersensitivity pneumonitis, detection of specific microbial antigens, including thermophilic actinomycetes or atypical mycobacteria, supports the diagnosis and informs exposure counselling at home or during occupational review.

  Genomic sequencing also serves a second purpose: ruling out infection masquerading as interstitial change. This is particularly relevant for patients on immunosuppression, those with human immunodeficiency virus and recipients of solid organ or haematopoietic transplants. Australian transplant programmes, coordinated through metropolitan hubs and linked regional clinics, increasingly request molecular pathogen panels alongside conventional staining to expedite treatment during the narrow therapeutic window of acute deterioration.

  Integrating fluid analysis with imaging and team review

  Multidisciplinary discussion remains the cornerstone of interstitial lung disease care, and refined fluid data strengthen every case presented. When high-resolution imaging is indeterminate or when biopsy carries unacceptable risk, lavage findings assume greater weight. Radiologists in tertiary centres such as Fiona Stanley Hospital in Perth or the Royal Melbourne Hospital now routinely correlate ground-glass attenuation with concurrent cytology and lymphocyte subsetting, allowing them to narrow the differential before any tissue diagnosis is attempted.

  The Australian model of formal multidisciplinary meetings, often documented with a structured radiology-pathology-medicine template, mirrors international consensus frameworks. Lavage findings have earned a dedicated column in many of these templates, ensuring that a high lymphocyte count, an atypical CD4/CD8 ratio or a positive metagenomic signal influences the consensus rather than appearing as an isolated laboratory footnote. Telehealth linkages, supported by Medicare-funded specialist video consultations, allow rural and remote physicians to present cases to metropolitan panels without long-distance travel, broadening access to expert interpretation.

  Practical realities across Australian healthcare

  Applying these advances in Australia requires awareness of the local funding framework. Bronchoscopy with lavage is reimbursed through the Medicare Benefits Schedule, yet molecular sequencing panels and certain proteomic assays remain unfunded in many jurisdictions, creating out-of-pocket cost considerations that vary by state. Public hospital laboratories absorb some of the cost, while private pathology providers offer differing menus, prompting clinicians to align requests with available local testing. Diagnostic devices and in vitro tests cleared for clinical use remain subject to oversight by the Therapeutic Goods Administration, an additional layer that shapes which assays reach routine practice.

  Occupational context also colours the case mix. Engineered stone silicosis, a condition that prompted national regulation and an eventual ban on certain high-silica products, remains an active area of clinical attention, and lavage lymphocytosis with compatible imaging supports compensation claims and workplace reviews. Aboriginal and Torres Strait Islander patients, who face a higher prevalence of certain environmental exposures and a greater burden of respiratory morbidity, benefit from culturally safe sampling pathways coordinated through community-controlled health organisations. Bushfire smoke exposure, recurrent across eastern Australia, has spurred interest in lavage-based inflammatory markers that may inform post-exposure surveillance, particularly among patients already living with fibrotic lung disease.

  A practical takeaway for clinicians is to request a standardised cellular report with absolute counts and lymphocyte subsets, supplement it with targeted molecular or proteomic assays for indeterminate cases, and present the integrated picture at a formal multidisciplinary meeting. Embedding lavage analysis within a structured Australian multidisciplinary framework and aligning it with locally available testing pathways ensures that each patient gains the diagnostic precision modern interstitial lung disease care can offer.

  Richard Russell Nuffield Department of Clinical Medicine, University of Oxford (United Kingdom)
• Mona Bafadhel King’s College London (United Kingdom)
  David Jackson Guy’s and St Thomas’ Hospital, King’s College London (United Kingdom)
• James Chalmers University of Dundee (United Kingdom)
  David Price University of Aberdeen (United Kingdom)